Molecular markers of prognosis and novel therapeutic strategies for urothelial cell carcinomas (Q36634023)

15 August 2017

1 reference

title

Molecular markers of prognosis and novel therapeutic strategies for urothelial cell carcinomas (English)

1 reference

15 August 2017

Christopher Y Thomas

1

1 reference

PubMed ID

17063322

15 August 2017

Dan Theodorescu

series ordinal

2

1 reference

15 August 2017

1 November 2006

1 reference

15 August 2017

World Journal of Urology

1 reference

15 August 2017

24

1 reference

15 August 2017

5

1 reference

15 August 2017

565-578

1 reference

https://scigraph.springernature.com/pub.10.1007/s00345-006-0119-6

15 August 2017

0 references

cites work

Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors

1 reference

https://api.crossref.org/works/10.1007%2FS00345-006-0119-6

Methylation of the E-cadherin gene in bladder neoplasia and in normal urothelial epithelium from elderly individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-006-0119-6

Absence of p53 overexpression and favorable response to cisplatin-based neoadjuvant chemotherapy in urothelial carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-006-0119-6

Expression of epidermal growth factor receptor in bladder cancer as related to established prognostic factors, oncoprotein (c-erbB-2, p53) expression and long-term prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-006-0119-6

p53 immunohistochemistry as an independent prognostic factor for superficial transitional cell carcinoma of the bladder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-006-0119-6

A multinomial Phase II study of lonafarnib (SCH 66336) in patients with refractory urothelial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-006-0119-6

Recent advances in understanding the antineoplastic mechanisms of farnesyltransferase inhibitors

21 January 2018

1 reference

12 December 2020

Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study

1 reference

12 December 2020

Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously.

1 reference

12 December 2020

Prognostic markers for bladder cancer: International Consensus Panel on bladder tumor markers

1 reference

12 December 2020

Clinical implications of the expression of epidermal growth factor receptors in human transitional cell carcinoma

1 reference

12 December 2020

Prediction of progression in pTa and pT1 bladder carcinomas with p53, p16 and pRb

1 reference

12 December 2020

Targeting death receptors in bladder, prostate and renal cancer

1 reference

12 December 2020

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

1 reference

12 December 2020

FGFR3 and Ras gene mutations are mutually exclusive genetic events in urothelial cell carcinoma.

1 reference

12 December 2020

Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer

1 reference

12 December 2020

FGFR3 and p53 protein expressions in patients with pTa and pT1 urothelial bladder cancer.

1 reference

12 December 2020

Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: a marker for disease progression

1 reference

12 December 2020

Long-term outcome related to epidermal growth factor receptor status in bladder cancer

1 reference

12 December 2020

Raf1, Aurora-A/STK15 and E-cadherin biomarkers expression in patients with pTa/pT1 urothelial bladder carcinoma; a retrospective TMA study of 246 patients with long-term follow-up.

1 reference

12 December 2020

Over-expression of p53 nuclear oncoprotein in transitional-cell bladder cancer and its prognostic value

1 reference

12 December 2020

Decreasing of p27(Kip1)and cyclin E protein levels is associated with progression from superficial into invasive bladder cancer

1 reference

12 December 2020

Handicapping the race to develop inhibitors of the phosphoinositide 3-kinase/Akt/mammalian target of rapamycin pathway

1 reference

12 December 2020

Specific targeted therapy of chronic myelogenous leukemia with imatinib

1 reference

12 December 2020

Graded activation of fibroblast growth factor receptor 3 by mutations causing achondroplasia and thanatophoric dysplasia

1 reference

12 December 2020

p53 expression compared with other prognostic factors in OMS grade-I stage-Ta transitional cell carcinoma of the bladder

1 reference

12 December 2020

p53 and RB expression predict progression in T1 bladder cancer

1 reference

12 December 2020

Clinical anticancer drug development: targeting the cyclin-dependent kinases

1 reference

12 December 2020

Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation

1 reference

12 December 2020

Prognostic value of the expression of E-cadherin and β-catenin in bladder cancer

1 reference

12 December 2020

Death receptors as targets of cancer therapeutics

1 reference

12 December 2020

Combined effects of p53, p21, and pRb expression in the progression of bladder transitional cell carcinoma

1 reference

12 December 2020

Expression of EphA2 and Ephrin A-1 in carcinoma of the urinary bladder

1 reference

12 December 2020

Human combinatorial Fab library yielding specific and functional antibodies against the human fibroblast growth factor receptor 3.

1 reference

12 December 2020

p53: traffic cop at the crossroads of DNA repair and recombination

1 reference

12 December 2020

Discovery of a novel Raf kinase inhibitor

1 reference

12 December 2020

Correlation and prognostic significance of p53, p21WAF1/CIP1 and Ki-67 expression in patients with superficial bladder tumors treated with bacillus Calmette-Guerin intravesical therapy

1 reference

12 December 2020

Loss of heterozygosity at the RB locus is frequent and correlates with muscle invasion in bladder carcinoma

1 reference

12 December 2020

Ral-GTPases: approaching their 15 minutes of fame

1 reference

12 December 2020

HGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivo

1 reference

12 December 2020

Overexpression of p53 protein in a high-risk population of patients with superficial bladder cancer before and after bacillus Calmette-Guérin therapy: correlation to clinical outcome

1 reference

12 December 2020

Ras, PI(3)K and mTOR signalling controls tumour cell growth

1 reference

12 December 2020

Gene expression in the urinary bladder: a common carcinoma in situ gene expression signature exists disregarding histopathological classification.

1 reference

12 December 2020

Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer

1 reference

12 December 2020

Genetic alterations in urothelial bladder carcinoma: an updated review

1 reference

12 December 2020

Molecular characterization of early-stage bladder carcinomas by expression profiles, FGFR3 mutation status, and loss of 9q.

1 reference

12 December 2020

Evaluation of epidermal growth factor receptor, transforming growth factor alpha, epidermal growth factor and c-erbB2 in the progression of invasive bladder cancer

1 reference

12 December 2020

Distinct requirements for Ras oncogenesis in human versus mouse cells

1 reference

12 December 2020

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

1 reference

12 December 2020

Epigenetic inactivation of Wnt inhibitory factor-1 plays an important role in bladder cancer through aberrant canonical Wnt/beta-catenin signaling pathway

1 reference

12 December 2020

HER-2/neu protein overexpression and gene amplification in human transitional cell carcinoma of the bladder.

1 reference

12 December 2020

Focus on bladder cancer

1 reference

12 December 2020

Evaluation of P53 protein overexpression, Ki67 proliferative activity and mitotic index as markers of tumour recurrence in superficial transitional cell carcinoma of the bladder

1 reference

12 December 2020

FGFR3 and Tp53 Mutations in T1G3 Transitional Bladder Carcinomas: Independent Distribution and Lack of Association with Prognosis

1 reference

12 December 2020

Bax to Bcl-2 ratio and Ki-67 index are useful predictors of neoadjuvant chemoradiation therapy in bladder cancer.

1 reference

12 December 2020

RhoGDI2 is an invasion and metastasis suppressor gene in human cancer

1 reference

12 December 2020

p21 and p53 Immunostaining and survival following systemic chemotherapy for urothelial cancer

1 reference

12 December 2020

Molecular staging of bladder cancer.

1 reference

12 December 2020

Cyclin-dependent kinase pathways as targets for cancer treatment

1 reference

12 December 2020

Prognostic factors in survival of patients with stage Ta and T1 bladder urothelial tumors: the role of G1-S modulators (p53, p21Waf1, p27Kip1, cyclin D1, and cyclin D3), proliferation index, and clinicopathologic parameters

1 reference

12 December 2020

Reduced expression of metastasis suppressor RhoGDI2 is associated with decreased survival for patients with bladder cancer

1 reference

12 December 2020

Cyclin D1 expression in transitional cell carcinoma of the bladder: correlation with p53, waf1, pRb and Ki67.

1 reference

12 December 2020

Infrequent involvement of mutations on neurofibromatosis type 1, H-ras, K-ras and N-ras in urothelial tumors

1 reference

12 December 2020

FGFR3 and TP53 gene mutations define two distinct pathways in urothelial cell carcinoma of the bladder

1 reference

12 December 2020

Gene-directed enzyme prodrug therapy: a current assessment.

1 reference

12 December 2020

Aberrant promoter methylation profile of bladder cancer and its relationship to clinicopathological features

1 reference

12 December 2020

Genetic and immunophenotype analyses of TP53 in bladder cancer: TP53 alterations are associated with tumor progression.

1 reference

12 December 2020

Targeting FGFR3 in multiple myeloma: inhibition of t(4;14)-positive cells by SU5402 and PD173074.

1 reference

12 December 2020

Promoter hypermethylation: a new therapeutic target emerges in urothelial cancer

1 reference

12 December 2020

Lipid posttranslational modifications. Farnesyl transferase inhibitors

1 reference

12 December 2020

Correlation of clinical outcome with p53 and p21 status in patients with advanced transitional-cell carcinoma treated with paclitaxel and carboplatin

1 reference

12 December 2020

Metastasis markers in bladder cancer: a review of the literature and clinical considerations

1 reference

12 December 2020

Prognostic value of p53 and MIB-1 in transitional cell carcinoma of the urinary bladder with regional lymph node involvement

1 reference

12 December 2020

Prognostic value of p53 overexpression in T1G3 bladder tumors treated with bacillus Calmette-Guérin therapy

1 reference

12 December 2020

Signal pathways which promote invasion and metastasis: critical and distinct contributions of extracellular signal-regulated kinase and Ral-specific guanine exchange factor pathways

1 reference

12 December 2020

Biomarker study of primary nonmetastatic versus metastatic invasive bladder cancer. National Cancer Institute Bladder Tumor Marker Network.

1 reference

12 December 2020

Expression of the endothelin axis in bladder cancer: relationship to clinicopathologic parameters and long-term survival

1 reference

12 December 2020

Gene expression profiling of progressive papillary noninvasive carcinomas of the urinary bladder

1 reference

12 December 2020

Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer

1 reference

12 December 2020

E-cadherin immunostaining of bladder transitional cell carcinoma, carcinoma in situ and lymph node metastases with long-term followup

1 reference

12 December 2020

p53 immunohistochemistry as a prognostic marker in bladder cancer. Playground for urology scientists?

1 reference

12 December 2020

Frequent p16/MTS1 inactivation in early stages of urothelial carcinoma of the bladder is not associated with tumor recurrence

1 reference

12 December 2020

FGFR3 as a therapeutic target of the small molecule inhibitor PKC412 in hematopoietic malignancies

1 reference

12 December 2020

Prognostic factors in stage T1 grade 3 bladder cancer survival: the role of G1-S modulators (p53, p21Waf1, p27kip1, Cyclin D1, and Cyclin D3) and proliferation index (ki67-MIB1).

1 reference

12 December 2020

FGFR3 and P53 characterize alternative genetic pathways in the pathogenesis of urothelial cell carcinoma.

1 reference

12 December 2020

Common and distinct elements in cellular signaling via EGF and FGF receptors

1 reference

12 December 2020

Bladder cancer stage and outcome by array-based comparative genomic hybridization

1 reference

12 December 2020

The transmembrane mutation G380R in fibroblast growth factor receptor 3 uncouples ligand-mediated receptor activation from down-regulation

1 reference

12 December 2020

Phase I study of PKC412 (N-benzoyl-staurosporine), a novel oral protein kinase C inhibitor, combined with gemcitabine and cisplatin in patients with non-small-cell lung cancer

1 reference

12 December 2020

CpG hypermethylation of promoter region and inactivation of E-cadherin gene in human bladder cancer

1 reference

12 December 2020

p53 and ki67 expression as prognostic factors for cancer-related survival in stage T1 transitional cell bladder carcinoma

1 reference

12 December 2020

Expression of the epidermal growth factor receptor family in normal and malignant urothelium

1 reference

12 December 2020

Role of activating fibroblast growth factor receptor 3 mutations in the development of bladder tumors.

1 reference

12 December 2020

Principles of tumor suppression

1 reference

12 December 2020

Protein farnesylation: implications for normal physiology, malignant transformation, and cancer therapy

1 reference

12 December 2020

Molecular grading of urothelial cell carcinoma with fibroblast growth factor receptor 3 and MIB-1 is superior to pathologic grade for the prediction of clinical outcome

1 reference

12 December 2020

Cyclin D1 expression in papillary superficial bladder cancer: its association with other cell cycle-associated proteins, cell proliferation and clinical outcome

1 reference

12 December 2020

Mutation spectrum of the 9q34 tuberous sclerosis gene TSC1 in transitional cell carcinoma of the bladder.

1 reference

12 December 2020

Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials.

1 reference

12 December 2020

The metastasis-associated gene CD24 is regulated by Ral GTPase and is a mediator of cell proliferation and survival in human cancer

1 reference

12 December 2020

erbB receptor expression patterns in human bladder cancer

1 reference

12 December 2020

Detection of circulating cancer cells expressing uroplakins and epidermal growth factor receptor in bladder cancer patients.

1 reference

12 December 2020

Prospective evaluation of the prognostic relevance of molecular staging for urothelial carcinoma

1 reference

12 December 2020

Continuous zebularine treatment effectively sustains demethylation in human bladder cancer cells

1 reference

12 December 2020

Significance of cyclin D1 overexpression in transitional cell carcinomas of the urinary bladder and its correlation with histopathologic features

1 reference

12 December 2020

Abnormal bcl-2 and pRb expression are independent correlates of radiation response in muscle-invasive bladder cancer

1 reference

12 December 2020

Loss of p21Waf1 expression is a strong predictor of reduced survival in primary superficial bladder cancers

1 reference

12 December 2020

High level of cFLIP correlates with resistance to death receptor-induced apoptosis in bladder carcinoma cells

1 reference

12 December 2020

Detection of micrometastases in pelvic lymph nodes in patients undergoing radical cystectomy for locally invasive bladder cancer by real-time reverse transcriptase-PCR for cytokeratin 19 and uroplakin II.

1 reference

12 December 2020

Anti-angiogenic activity of selected receptor tyrosine kinase inhibitors, PD166285 and PD173074: implications for combination treatment with photodynamic therapy

1 reference

12 December 2020

The p53 pathway: targets for the development of novel cancer therapeutics.

1 reference

12 December 2020

Phase I study of BMS-214662, a farnesyl transferase inhibitor in patients with acute leukemias and high-risk myelodysplastic syndromes

1 reference

12 December 2020

Lymphovascular invasion is independently associated with overall survival, cause-specific survival, and local and distant recurrence in patients with negative lymph nodes at radical cystectomy

1 reference

12 December 2020

Prognostic relevance of methylation markers in patients with non-muscle invasive bladder carcinoma.

1 reference

12 December 2020

Analysis of gene induction in human fibroblasts and bladder cancer cells exposed to the methylation inhibitor 5-aza-2'-deoxycytidine.

1 reference

12 December 2020

Development of farnesyl transferase inhibitors: a review

1 reference

12 December 2020

Preclinical studies of fibroblast growth factor receptor 3 as a therapeutic target in multiple myeloma

1 reference

12 December 2020

The role of bcl-2, p53, and ki-67 index in predicting tumor recurrence for low grade superficial transitional cell bladder carcinoma

1 reference

12 December 2020

Prognostic value of MIB-1 score, p53, EGFr, mitotic index and papillary status in primary superficial (Stage pTa/T1) bladder cancer: a prospective comparative study. The Finnbladder Group

1 reference

12 December 2020

Gene therapy: the challenges of translating laboratory research into clinical practice

1 reference

12 December 2020

Understanding urothelial carcinoma through cancer pathways

1 reference

12 December 2020

Apoptosis, p53, bcl-2, and Ki-67 in invasive bladder carcinoma: possible predictors for response to radiochemotherapy and successful bladder preservation

1 reference

12 December 2020

A Molecular Signature in Superficial Bladder Carcinoma Predicts Clinical Outcome

1 reference

12 December 2020

High-density single nucleotide polymorphism array defines novel stage and location-dependent allelic imbalances in human bladder tumors

1 reference

12 December 2020

Historical review: Endothelin

1 reference

12 December 2020

Multicentre EORTC study 16997: feasibility and phase II trial of farnesyl transferase inhibitor & gemcitabine combination in salvage treatment of advanced urothelial tract cancers

1 reference

12 December 2020

RAL GTPases are linchpin modulators of human tumour-cell proliferation and survival

1 reference

12 December 2020

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

1 reference

12 December 2020

Predicting response to methotrexate, vinblastine, doxorubicin, and cisplatin neoadjuvant chemotherapy for bladder cancers through genome-wide gene expression profiling

1 reference

12 December 2020

RalA and RalB: antagonistic relatives in cancer cell migration

1 reference

12 December 2020

Species- and cell type-specific requirements for cellular transformation

1 reference

12 December 2020

N-(cycloalkylamino)acyl-2-aminothiazole inhibitors of cyclin-dependent kinase 2. N-[5-[[[5-(1,1-dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl]-4- piperidinecarboxamide (BMS-387032), a highly efficacious and selective antitumor agent

1 reference

12 December 2020

The role of Ral A in epidermal growth factor receptor-regulated cell motility.

1 reference

12 December 2020

Prognostic value of p53 nuclear overexpression in patients with invasive bladder cancer treated with neoadjuvant MVAC

1 reference

12 December 2020

Can p53 staining be used to identify patients with aggressive superficial bladder cancer?

1 reference

12 December 2020

Detection of occult tumor cells in lymph nodes from bladder cancer patients by MUC7 nested RT-PCR.

1 reference

12 December 2020

EphB4 receptor tyrosine kinase is expressed in bladder cancer and provides signals for cell survival.

1 reference

12 December 2020

Urothelial tumorigenesis: a tale of divergent pathways

1 reference

12 December 2020

A small-molecule agonist of the Wnt signaling pathway

1 reference

12 December 2020

The fibroblast growth factor receptor 3 (FGFR3) mutation is a strong indicator of superficial bladder cancer with low recurrence rate

1 reference

12 December 2020

Comprehensive analysis of CDKN2A status in microdissected urothelial cell carcinoma reveals potential haploinsufficiency, a high frequency of homozygous co-deletion and associations with clinical phenotype.

1 reference

12 December 2020

Altered expression of the retinoblastoma gene product: prognostic indicator in bladder cancer

1 reference

12 December 2020

Predictive value of cell cycle markers p53, MDM2, p21, and Ki-67 in superficial bladder tumor recurrence

1 reference

12 December 2020

Accumulation of nuclear p53 and tumor progression in bladder cancer.

1 reference

12 December 2020

Bladder cancer outcome and subtype classification by gene expression

1 reference

12 December 2020

Evaluation of p21WAF1/CIP1 and cyclin D1 expression in the progression of superficial bladder cancer. Finbladder Group

1 reference

12 December 2020

Cell cycle regulators in bladder cancer: a multivariate survival study with emphasis on p27Kip1

1 reference

12 December 2020

Preclinical and clinical development of the oral multikinase inhibitor sorafenib in cancer treatment

1 reference

12 December 2020

Mechanisms of disease: angiogenesis in urologic malignancies.

1 reference

12 December 2020

Repeated intravesical instillations of an adenoviral vector in patients with locally advanced bladder cancer: a phase I study of p53 gene therapy

1 reference

12 December 2020

Activation of FGF receptors by mutations in the transmembrane domain

1 reference

12 December 2020

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

1 reference

12 December 2020

Prediction of recurrence in Ta urothelial cell carcinoma by real-time quantitative PCR analysis: A microarray validation study

1 reference

12 December 2020

Histone deacetylase inhibitors

1 reference

12 December 2020

Two molecular pathways to transitional cell carcinoma of the bladder.

1 reference

12 December 2020

Cyclin D1 protein overexpression is related to tumor differentiation, but not to tumor progression or proliferative activity, in transitional cell carcinoma of the bladder

1 reference

12 December 2020

Immunohistochemical demonstration of cyclin D1 in bladder cancers as an inverse indicator of invasiveness but not an independent prognostic factor

1 reference

12 December 2020

Targeting the ERK signaling pathway in cancer therapy

1 reference

12 December 2020

p53 Gene mutations in superficial bladder cancer.

1 reference

12 December 2020

Review Article: The Role of Ras Superfamily Proteins in Bladder Cancer Progression

1 reference

12 December 2020

The inhibitory anti-FGFR3 antibody, PRO-001, is cytotoxic to t(4;14) multiple myeloma cells

1 reference

12 December 2020

Bcl-2 expression identifies patients with advanced bladder cancer treated by radiotherapy who benefit from neoadjuvant chemotherapy

1 reference

12 December 2020

Prognostic factors in transitional cell cancer of the bladder: an emerging role for Bcl-2 and p53

1 reference

12 December 2020

Molecular subtypes of bladder cancer: Jekyll and Hyde or chalk and cheese?

1 reference

12 December 2020

Activation of RalA is critical for Ras-induced tumorigenesis of human cells.

1 reference

12 December 2020

Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy

1 reference

12 December 2020

Pretreatment p53 nuclear overexpression as a prognostic marker in superficial bladder cancer treated with Bacillus Calmette-Guérin (BCG).

1 reference

12 December 2020

Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas.

1 reference

12 December 2020

P16 immunoreactivity is an independent predictor of tumor progression in minimally invasive urothelial bladder carcinoma

1 reference

12 December 2020

The prognostic value of angiogenesis and metastasis-related genes for progression of transitional cell carcinoma of the renal pelvis and ureter

1 reference

12 December 2020

Prognostic implications of p53 gene mutations in bladder tumors.

1 reference

12 December 2020

Gastrointestinal stromal tumors and the evolution of targeted therapy.

1 reference

12 December 2020

p53 nuclear immunoreactivity as a predictor of response and outcome following chemotherapy for metastatic bladder cancer

1 reference

12 December 2020

Mechanisms of Disease: genetic and epigenetic alterations that drive bladder cancer

1 reference

12 December 2020

The molecular and cellular biology of HER2/neu gene amplification/overexpression and the clinical development of herceptin (trastuzumab) therapy for breast cancer.

1 reference

12 December 2020

P53 as a prognostic marker for bladder cancer: a meta-analysis and review.

1 reference

12 December 2020

p53, p21, pRB, and p16 expression predict clinical outcome in cystectomy with bladder cancer

1 reference

12 December 2020

The small G-protein RalA stimulates metastasis of transformed cells.

1 reference

12 December 2020

Practicalities of drugging the phosphatidylinositol-3-kinase/Akt cell survival signaling pathway

1 reference

12 December 2020

p53 and treatment of bladder cancer

1 reference

12 December 2020

In vivo target modulation and biological activity of CHIR-258, a multitargeted growth factor receptor kinase inhibitor, in colon cancer models

1 reference

12 December 2020

Overexpression of c-met as a prognostic indicator for transitional cell carcinoma of the urinary bladder: a comparison with p53 nuclear accumulation

1 reference

12 December 2020

Correlation between histologic findings and cytogenetic abnormalities in bladder carcinoma: a FISH study

1 reference

12 December 2020

Gene therapy progress and prospects: cancer gene therapy using tumour suppressor genes.

1 reference

12 December 2020

Molecular and Immunohistochemical Analysis of the Prognostic Value of Cell-Cycle Regulators in Urothelial Neoplasms of the Bladder

1 reference

12 December 2020

A phase II trial of R115777, an oral farnesyl transferase inhibitor, in patients with advanced urothelial tract transitional cell carcinoma

1 reference

12 December 2020

Ki-67 MIB1 labelling index and the prognosis of primary TaT1 urothelial cell carcinoma of the bladder

1 reference

12 December 2020

Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma: results of a multicenter phase II National Cancer Institute trial

1 reference

12 December 2020

Oncogenic properties of the mutated forms of fibroblast growth factor receptor 3b.

1 reference

12 December 2020

Overexpression of c-erbB-2 oncoprotein in muscle-invasive bladder carcinoma: relationship with gene amplification, clinicopathological parameters and prognostic outcome

1 reference

12 December 2020

Defining molecular profiles of poor outcome in patients with invasive bladder cancer using oligonucleotide microarrays.

1 reference

12 December 2020

Postoperative nomogram predicting risk of recurrence after radical cystectomy for bladder cancer

1 reference

12 December 2020

Mutations within the kinase domain and truncations of the epidermal growth factor receptor are rare events in bladder cancer: implications for therapy.

1 reference

12 December 2020

What we could do now: molecular pathology of bladder cancer

1 reference

12 December 2020

Detection of epidermal growth factor receptor mRNA in peripheral blood: a new marker of circulating neoplastic cells in bladder cancer patients

1 reference

12 December 2020

10.1007/S00345-006-0119-6

Identifiers

DOI

1 reference

15 August 2017

1 reference

PubMed ID

17063322